Sanofi Nabs Priority Review For New Pompe Drug
And Rilzabritib Gets US Fast Track For ITP
The French drugmaker's follow up to Myozyme – avalglucosidase alfa – is in line for a potential US approval by May next year after the US FDA agreed to a speedy review of the enzyme replacement therapy, unlike its European counterparts.
